This study describes the development of DELFI-TF using a large cohort of RAS/BRAF mutant CRC patients with metastatic liver disease and the validation of the method in an independent cohort of CRC patients with RAS/BRAF wild-type tumors as well as in a cohort of lung cancer patients treated with immune checkpoint blockade. This evidence concerns the gene TF and colorectal carcinoma.